News
-
2022-10-05
AnnJi Pharmaceutical Co., Ltd. Announces the Initiation of a Clinical Study of AJ201 for the Treatment of SBMA
-
2022-08-28
AnnJi’s Pleiotropic Compounds Featured in the International Journal of Dermatology and Clinical Research (IJDCR)
-
2022-03-11
AnnJi Pharmaceutical’s HDAC6 selective inhibitor received “Grass Roots” Support Program Award sponsored by Boehringer Ingelheim, Taiwan
-
2020-11-23
Merger between AnnJi Pharmaceutical Company (AnnJi) and Allianz Pharmascience (Allianz) gives rise to Taiwan’s leading drug developer in neurodegeneration and dermatology
-
2020-07-14
Positive Feedback of AJ302 from US-FDA reviewers